Studies conducted to discover the linking bridge between GSK-3 and neuropathological features of Alzheimer’s disease have discovered the tau protein as a widely recognized substrate of GSK-3. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.